Coagulation Factor Articles & Analysis
4 news found
It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. ...
A comprehensive summary of ASC618 preclinical development and dose translation approach will be presented in a poster: “Pharmacology, Toxicology and Safety Studies of ASC618, a Second-Generation Factor VIII Gene Therapy for Hemophilia A Development” on Tuesday, May 17 (Hall D, Poster Board Number: Tu-288, 5:30 PM – 6:30 PM ET, abstract number: 783). ...
FDA Orphan Drug Designation in 2020 for ASC618, these regulatory achievements will significantly facilitate the scientific and clinical development of ASC 618’s gene replacement therapies for hemophilia A, reflecting: A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement ...